Optimizing use of opiates in the management of cancer pain
- PMID: 18360655
- PMCID: PMC1936364
- DOI: 10.2147/tcrm.2006.2.4.447
Optimizing use of opiates in the management of cancer pain
Abstract
Cancer pain is often suboptimally managed. The underestimation and undertreatment continues to be a problem despite the availability of consensus-based guidelines. Most patients with cancer develop pain. The prevalence and severity of pain among cancer patients varies according to primary and metastatic sites and stage of disease. Opioid therapy is the cornerstone of management of severe chronic pain in the field of cancer patients and in general in palliative care medicine. Since this class of drugs is the cornerstone of the treatment, optimizing its use may be useful in clinical practice. For this purpose we focused on 4 distinct issues: 1) How to implement the use the opioids in cancer patients; 2) How to optimise the use of morphine in cancer patients; 3) The management of side effects and opioid switching; 4) What is the role of other potent opioids. A holistic approach including an appropriate use of opioids may improve pain control in most cancer patients, particularly for those with advanced disease.
Similar articles
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.Pain Physician. 2017 Feb;20(2S):S3-S92. Pain Physician. 2017. PMID: 28226332
-
A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.Curr Med Res Opin. 2005 Feb;21(2):271-80. doi: 10.1185/030079904X20312. Curr Med Res Opin. 2005. PMID: 15801998
-
Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?Curr Med Res Opin. 2010 Jul;26(7):1677-84. doi: 10.1185/03007995.2010.483941. Curr Med Res Opin. 2010. PMID: 20465361 Review.
-
Pain management in palliative care. Morphine and the 'new' opioids in 2000.Aust Fam Physician. 2000 Dec;29(12):1167-71. Aust Fam Physician. 2000. PMID: 11140226
Cited by
-
Association between pain medication misuse, psychological distress, and opioid use disorder among adults with lifetime cancer diagnosis in the United States.Support Care Cancer. 2025 Jun 28;33(7):638. doi: 10.1007/s00520-025-09713-1. Support Care Cancer. 2025. PMID: 40581686
-
Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.Eur J Pain. 2016 Oct;20(9):1513-8. doi: 10.1002/ejp.875. Epub 2016 Apr 7. Eur J Pain. 2016. PMID: 27062079 Free PMC article. Clinical Trial.
-
An update on the safety of prescribing opioids in pediatrics.Expert Opin Drug Saf. 2019 Feb;18(2):127-143. doi: 10.1080/14740338.2019.1571037. Epub 2019 Jan 25. Expert Opin Drug Saf. 2019. PMID: 30650988 Free PMC article. Review.
-
Opioid use in patients undergoing treatment for oral cavity cancer.J Pain Manag. 2020;13(2):167-173. J Pain Manag. 2020. PMID: 34457108 Free PMC article.
-
An acceptance and commitment therapy-based intervention for opioid use disorder risk in individuals with cancer: A treatment development study.J Contextual Behav Sci. 2023 Apr;28:226-234. doi: 10.1016/j.jcbs.2023.04.006. Epub 2023 Apr 25. J Contextual Behav Sci. 2023. PMID: 37333769 Free PMC article.
References
-
- Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage. 1997;13:254–61. - PubMed
-
- Ashby MA, Martin P, Jackson KA. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust. 1999;170:68–71. - PubMed
-
- Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double blind, emergency department study. Am J Emerg Med. 1997;15:335–40. - PubMed
-
- Bruera E, MacMillian K, Hanson J, et al. The cognitive effects of the administration of arcotics analgesics in patients with cancer pain. Pain. 1989;39:13–16. - PubMed
-
- Bruera E, Miller L, McCallion J, et al. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage. 1992;7:192–5. - PubMed
LinkOut - more resources
Full Text Sources